PRIMENENIE RIBOSOMAL'NOY VAKTsINY (RIBOMUNIL) V PROFILAKTIKE RESPIRATORNYKh ZABOLEVANIY U DETEY


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article is devoted to the efficiency of application of Ribomunyl for the prevention of respiratory infections in children. Ribomunyl is the ribosomal immunomodulator of bacterial origin. It is composed of ribosomal fractions of Streptococcus pneumoniae, S. pyogenes, Haemophilus influenzae, Klebsiella pneumoniae, as well as cell wall proteoglycans of K. pneumoniae. All double-blind, placebocontrolled studies have shown high efficiency of Ribomunyl in preventing recurrent ENT and bronchopulmonary infections. The drug reduced the number, severity and duration of infectious episodes, antibiotic courses, concomitant medications (antitussives, expectorants, antipyretics, etc.) and the number of days missing school or missing work of parents. Decrease of need to use antibiotics during treatment with a Ribomunyl is important; this reduces the likelihood of antibacterial resistance.

Full Text

Restricted Access

References

  1. Bellanti J.A. Recurrent respiratory tract infections in pediatric patients. Drugs. 1997; 54(Suppl. 1): 1-4.
  2. Del-Rio-Navarro B.E., Espinosa-Rosales F.J., Flenady V., Sienra-Monge J.J.L. Immunostimulants for preventing respiratory tract infection in children. Cochrane Database Systematic Rev. 2006; Issue 4: CD004974.
  3. Геппе Н.А., Снегоцкая М.Н. Диагностический поиск и принципы лечения кашля у детей. Consilium medicum. Педиатрия. 2012; 1: 52-5.
  4. Cohen R. Enquete nationale sur les criteres de prescriptiondune antibiotherapie dans les rhinopharyngites en pediatrie en ville [National survey regarding antibiotic treatment for pediatric rhino-pharyngitis by private physians(in France)]. Ann Pediatr (Paris). 1992; 39: 195-201.
  5. Пикуза О.И., Закирова А.М., Хакимова А.Ф. Клинико-иммунологическая эффективность бактериальных лизатов у часто болеющих детей. РМЖ. 2012; 96(2): 45-7.
  6. Klein J.O. Nonimmune strategies for prevention of otitis media. Pediatr. Infect. Dis. J. 2000; 19: S89-92.
  7. De Baets F., Kint J., Pauwels R., et al. IgG subclass deficiencyin children with recurrent bronchitis. Eur. J. Pediatr. 1992; 151: 274-78.
  8. David J.R., Rosen F.S. Deficiencies in immunoglobulinsand cell-mediated immunity (CD-Rom). Chapter IX. Scientific American Medicine (New York NY), SAM-CD, 2000.
  9. Paradise J.L. Tonsillectomy and adenoidectomy in children: Indications and contraindications. http://www.uptodate.com, 12, 2013.
  10. Опыт применения Рибомунила в Российской педиатрической практике. Сборник научных трудов / Под ред. Н.А. Коровиной. М., 2002.
  11. Афиногенова В.П., Лукачев И.В., Костинов М.П. Иммунотерапия: механизм действия и клиническое применение иммунокорригирующих препаратов. Лечащий врач. 2010; 4.
  12. Krachenbubl J.P., Neutra M.R. Epithelial M cells: differentiation and function. Anna. Rev. Cell. Dev. Biol. 2001; 16: 301-32.
  13. Cahot E., Libon C., Kernels S., el al. Translocation of ribosomal immuno-stimulant through an in vitro-reconstituted digestive barrier containing M-like cells. Scand. J. Immunol. 2000; 52: 588-94.
  14. Hbabi-Haddioui L., Roques C. Inhibition ol Strepococcus pneumoniae adhesion by specific salivary IgA after oral immunization with a ribosomal immunostimulant. Drugs. 1997; 54: 29-32.
  15. Boccaccio C., Jacod S., Kaiser A., el al. Identification of a clinical-grade maturation factor for dendritic cells. J. Immunother. 2002; 25: 88-96.
  16. Jongmans W., Tiemessen D.M., van Vlodrop I.J., et al. Th1-polarizing capacity of clinical-grade dendritic cells triggered by Ribomunyl but is compromised by PGE2. J. Immunother. 2005; 28: 480-87.
  17. Chahtour A., Jeannin P., Gauchat J.F., el al. Direct bacterial protein PAMPs recognition by human NK cells involves TLRs and triggers a-defensin production. Blood. 2004; 104: 778-83.
  18. Hertzog P.J., O'neil L.A., Hamilton J.A. The interferon in TLR signalling: more than just antiviral. Trends Immunol. 2003; 24: 534-39.
  19. Zanib C., Bene M.C., Perruchet A.M. et al. Bacterial crude extracts of ribosomes are recognized similary by peripheral and mucosal B cells. PPMS Immunol. Med. Microbiol. 1994; 10: 11-8.
  20. Hbabi-Haddioui L., Roques C. Inhibition ol Strepococcus pneumoniae adhesion by specific salivary IgA after oral immunization with a ribosomal immunostimulant. Drugs. 1997; 54: 29-32.
  21. Giovannini M., Fiocchi A., Sala M., el al. Immucytal in the prevention and treatment of recurrent upper respiratory tract infection in children: a randomized, placebo-controlled, double-blind study. Int. J. Immunother. 2000; 16: 67-75.
  22. Mora R., Barbiery M., Passali G., el al. A preventive measure tor otitis media in children with upper respiratory tract infections. Int. J. Pediatr. Otorhinolaryngol. 2002; 63: 111-18.
  23. Bousquet J., Fiocchi A. Prevention of recurrent respiratory tract infections in children using a ribosomal immunotherapeutic agent: a clinical review. Paediatr. Drugs. 2006; 8(4): 235-43.
  24. Орлова С.Н., Рывкин А.И. Рибомунил в профилактике рецидивов стенозирующего ларинготрахеита у детей. Вопросы современной педиатрии. 2008; 7(2): 68-71.
  25. Bellami J.A., Olivieri D., Seranno E. Ribosomal immunostimulation: assessment of studies evaluating its clinical relevance in the prevention ol upper and lower respiratory tract infections in children and adults. BioDrugs. 2003; 17: 355-67.
  26. Boyle P., Bellanto J.A., Robertson C. Mela-analysis of published clinical trials of a ribosomal vaccine (Ribomunyl® in prevention of respiratory infections. BioDrugs. 2000; 14: 389-408.
  27. Galioto G.B., Galioto P., Mevio E., et al. Efficacv and tolerability of Immucytal® in the prevention and treatment of respiratory tract infectuins: a randomized, placebo-controlled, double-blind study. Int. J. Immunother. 2001; 17: 31-40.
  28. Gramiccioni E., Girbino G., Pelucco D. Efflicacy and tolerabilily of Immucytal® in the prevention of upper respiratory tract infections: a randomized, placebo-controlled, double-blind study. J. Clin. Res. 2001; 4: 53-63.
  29. Булгакова В.А., Балаболкин И.И., Сенцова Т.Б. и др. Применение топических иммунотропных препаратов при интеркуррентных инфекциях у детей с аллергической патологией. Педиатрическая фармакология. 2006; 3(4): 56-62.
  30. Богомолова И.К., Носков К.Г. Эффективность вакцинотерапии рибомунилом у больных бронхиальной астмой. Забайкальский медицинский вестник. 2010; 1: 3-5.
  31. Богомолова И.К., Бишарова Г.И., Огнева Е.Ю., Второва Г.П. Результаты применения препарата рибомунил в комплексном лечении бронхиальной астмы у детей. Бюллетень ВСНЦ СО РАМН. 2006; 1(47): 7-10.
  32. Бережной В.В., Е.Н. Охотникова, Е.Н. Коломоец. Рибомунил: актуальность применения, эпидемиологическая и клиническая эффективность использования в украинской педиатрической практике. Совр. педитария. 2007; 3(16): 148-51.
  33. Мокия-Сербина С.А., Литвинова Т.В., Пономарева Л.И., Медведева В.А. Клиникоиммунологическая эффективность рибомунила при персистенции респираторных вирусов у детей, больных бронхиальной астмой. Современная педиатрия. 2010; 2(30): 131-35.
  34. Hoffman J.A. The effect of bacterial ribosomes extracts on clinical and immunological parameters in children with recurrent infections of respiratory tract with bronchospastic symptoms [abstract no. 616] / XXI Congress of EAACI, 2002, Jun. 1-5; Naples.
  35. Vautel J.M., Cauquil J., Perruchet A.M., et al. Prevention of recurrent ear, nose and throat infections in young children with Ribomunyl: double-blind, placebo-controlled study. Curr. Ther. Res. 1993; 53; 722-29.
  36. Portales P., Clot J. Новый взгляд на иммуностимуляторы: фокус на фармакологию рибомунила. Biodrugs. 2006; 20(2): 81-4.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies